Table 1.

Five-Year Overall Survival of Patient Subsets by Era

Patient Group	No.	5-Year Survival ± SE (%)						% Reduction2000-2005 v 1990-1994	P *
		1990-1994	No. of Patients	1995-1999	No. of Patients	2000-2005	No. of Patients
All patients	21,626	83.7 ± 0.4	7,304	87.7 ± 0.4	7,169	90.4 ± 0.5	7,153	41	< .001
Age group, years
< 1	461	47.9 ± 4.1	154	48.1 ± 4.3	148	53.2 ± 5.4	159	10	.4520
1-9.99	16,578	88.2 ± 0.4	5,599	91.7 ± 0.4	5,523	94.1 ± 0.4	5,456	50	< .001
≥ 10	4,587	70.8 ± 1.2	1,551	76.9 ± 1.2	1,498	81.6 ± 1.3	1,538	37	< .001
10-14.99	3,072	72.8 ± 1.4	1,094	78.9 ± 1.4	1,001	84.7 ± 1.5	977	44	< .001
≥ 15	1,515	66.1 ± 2.3	457	72.9 ± 2.2	497	75.9 ± 2.6	561	29	.0025
Sex
Male	12,155	82.7 ± 0.6	4,117	86.3 ± 0.6	4,057	89.9 ± 0.6	3,981	42	< .001
Female	9,471	84.9 ± 0.7	3,187	89.5 ± 0.6	3,112	91.0 ± 0.7	3,172	40	< .001
Race
White	15,759	86.3 ± 0.5	5,410	88.9 ± 0.5	4,890	91.1 ± 0.5	5,242	35	< .001
Black	1,474	75.3 ± 2.0	535	80.7 ± 1.9	472	87.8 ± 2.1	425	51	< .001
Other	4,393	77.0 ± 1.2	1,359	86.3 ± 0.9	1,807	88.1 ± 1.2	1,486	48	< .001
Ethnicity
Hispanic	2,589	82.0 ± 1.8	547	86.2 ± 1.4	675	87.6 ± 1.2	1,367	31	.0076
Non-Hispanic	12,528	87.0 ± 0.6	3,626	88.5 ± 0.6	3,377	91.4 ± 0.5	5,525	34	< .001
Unknown	6,509	80.0 ± 0.7	3,131	87.1 ± 0.6	3,117	83.6 ± 3.0	261	18	< .001
Immunophenotype
B cell	16,880	84.9 ± 0.5	5,068	88.3 ± 0.4	5,830	91.1 ± 0.5	5,982	41	< .001
T cell	1,831	70.7 ± 1.7	748	80.7 ± 1.7	624	81.6 ± 2.2	459	37	< .001
NCI risk group
Standard risk	14,154	90.2 ± 0.5	4,624	92.7 ± 0.4	4,674	95.0 ± 0.4	4,856	49	< .001
High risk		73.8 + 0.9	2,680	79.8 ± 0.9	2,494	82.9 ± 1.1	2,286	32	< .001

Abbreviation: NCI, National Cancer Institute.

^*The P values were computed by comparing the survival curves among all three eras.